You are viewing the site in preview mode
Skip to main content
| |
All
|
China
|
South Asia
|
East Asia
|
North Africa
|
Middle East
|
Latin America
|
Russia
|
|---|
|
Patients with macrovascular complications, n (%)
|
17,806 (27.2)
|
2,342 (21.3)
|
4,946 (23.3)
|
2,685 (26.8)
|
979 (24.2)
|
4,293 (28.7)
|
335 (29.4)
|
2,226 (72.4)
|
|
Patients with microvascular complications, n (%)
|
35,078 (53.5)
|
5,467 (49.6)
|
8,293 (39.0)
|
5,615 (56.0)
|
2,397 (59.4)
|
9,847 (65.8)
|
715 (62.8)
|
2,744 (89.3)
|
|
Renal disease, n (%)
|
18,271 (27.9)
|
2,455 (22.3)
|
4,321 (20.3)
|
2,845 (28.4)
|
1,077 (26.7)
|
6,108 (40.8)
|
376 (33.0)
|
1,089 (35.4)
|
|
Eye problems, n (%)
|
17,198 (26.3)
|
2,430 (22.1)
|
3,464 (16.3)
|
2,380 (23.7)
|
1,354 (33.5)
|
5,081 (33.9)
|
368 (32.3)
|
2,121 (69.0)
|
|
Foot ulcer, n (%)
|
3,538 (5.4)
|
274 (2.5)
|
1,046 (4.9)
|
536 (5.3)
|
147 (3.6)
|
1,289 (8.6)
|
85 (7.5)
|
161 (5.2)
|
|
Neuropathy, n (%)
|
25,179 (38.4)
|
3,671 (33.3)
|
5,234 (24.6)
|
3,706 (36.9)
|
1,530 (37.9)
|
7,995 (53.4)
|
491 (43.1)
|
2,552 (83.0)
|
- Note: due to the observational nature of this study, not all baseline data were recorded.
